Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hoyle M"" wg kryterium: Autor


Tytuł :
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
Autorzy :
Joulain, F
Proskorovsky, I
Allegra, C
Tabernero, J
Hoyle, M
Iqbal, S U
Van Cutsem, E
Pokaż więcej
Temat :
COLON cancer
CLINICAL trials
IRINOTECAN
DRUG use testing
FOLINIC acid
CANCER treatment
THERAPEUTICS
Źródło :
British Journal of Cancer; 10/1/2013, Vol. 109 Issue 7, p1735-1743, 9p
Czasopismo naukowe
Tytuł :
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Autorzy :
Thompson Coon, J. S.
Liu, Z.
Hoyle, M.
Rogers, G.
Green, C.
Moxham, T.
Welch, K.
Stein, K.
Pokaż więcej
Temat :
BEVACIZUMAB
ANTINEOPLASTIC agents
RENAL cell carcinoma
CANCER treatment
MEDICAL research
METASTASIS
RENAL cancer
CANCER patients
Źródło :
British Journal of Cancer; 7/21/2009, Vol. 101 Issue 2, p238-243, 6p, 1 Diagram, 4 Charts
Czasopismo naukowe
Tytuł :
Manganese toxicity in yellow birch ( Betula alleghaniensis Britton) seedlings.
Autorzy :
Hoyle, M.
Pokaż więcej
Źródło :
Plant & Soil; Mar1972, Vol. 37 Issue 1, p229-232, 4p
Czasopismo naukowe
Tytuł :
Effects of the chemical environment on yellow-birch root development and top growth.
Autorzy :
Hoyle, M.
Pokaż więcej
Źródło :
Plant & Soil; Aug1971, Vol. 35 Issue 1-3, p623-633, 11p
Czasopismo naukowe
Tytuł :
Chemical sterilization of bacterially contaminated bone without destruction of osteogenic potential.
Autorzy :
Dahners, L. E.
Hoyle, M.
Pokaż więcej
Źródło :
Journal of Orthopaedic Trauma; Sep1989, Vol. 3 Issue 3, p241-244, 4p
Czasopismo naukowe
Tytuł :
Use of slowscan technology in the North Slope Borough Telehealth Project.
Autorzy :
Hoyle, M F
Jamieson, L N
Pokaż więcej
Źródło :
International Journal of Technology Assessment in Health Care; 1/ 1/1989, Vol. 5 Issue 1, p63-71, 9p
Czasopismo naukowe
Tytuł :
RESPONSE OF YELLOW BIRCH IN ACID SUBSOIL TO MACRONUTRIENT ADDITIONS.
Autorzy :
Hoyle, M. C.
Pokaż więcej
Źródło :
Soil Science; Nov1969, Vol. 108 Issue 5, p354-358, 5p
Periodyk
Tytuł :
AN INEXPENSIVE PORTABLE UNIT FOR PERCHLORIC ACID DIGESTIONS AND SEMIMICRO-KJELDAHL DETERMINATIONS.
Autorzy :
Mader, D. L.
Hoyle, M. C.
Pokaż więcej
Źródło :
Soil Science; Nov1964, Vol. 98 Issue 5, p295-299, 5p
Periodyk
Tytuł :
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Autorzy :
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Griffin E; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lucherini S; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Talens-Bou J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Sherriff D; Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK.
Napier M; Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Ramage J; Neuroendocrine Tumour Service, King's College Hospital NHS Foundation Trust, London, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2018 Sep; Vol. 22 (49), pp. 1-326.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Everolimus/*therapeutic use
Neuroendocrine Tumors/*drug therapy
Octreotide/*analogs & derivatives
Organometallic Compounds/*therapeutic use
Radioisotopes/*therapeutic use
Sunitinib/*therapeutic use
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cost-Benefit Analysis ; Digestive System Neoplasms/drug therapy ; Digestive System Neoplasms/pathology ; Disease Progression ; Everolimus/adverse effects ; Everolimus/economics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Neoplasm Metastasis ; Neuroendocrine Tumors/pathology ; Octreotide/adverse effects ; Octreotide/economics ; Octreotide/therapeutic use ; Organometallic Compounds/adverse effects ; Organometallic Compounds/economics ; Quality-Adjusted Life Years ; Radioisotopes/adverse effects ; Radioisotopes/economics ; Randomized Controlled Trials as Topic ; Sunitinib/adverse effects ; Sunitinib/economics
Czasopismo naukowe
Tytuł :
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Autorzy :
Dickson R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK. .
Boland A; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Duarte R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Kotas E; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Woolacott N; Centre for Reviews and Dissemination, University of York, York, UK.
Hodgson R; Centre for Reviews and Dissemination, University of York, York, UK.
Riemsma R; Kleijnen Systematic Reviews, York, UK.
Grimm S; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Ramaekers B; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Joore M; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Büyükkaramikli N; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Kaltenthaler E; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Stevenson M; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Pandor A; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Edwards S; BMJ Technology Assessment Group, BMJ, London, UK.
Hoyle M; Peninsula Technology Assessment Group, University of Exeter Medical School, Exeter, UK.
Shepherd J; Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK.
Armoiry X; Warwick Evidence, University of Warwick, Coventry, UK.
Brazzelli M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Pokaż więcej
Źródło :
Applied health economics and health policy [Appl Health Econ Health Policy] 2018 Aug; Vol. 16 (4), pp. 429-432.
Typ publikacji :
Editorial
MeSH Terms :
Drug Approval*/methods
Drug Approval*/organization & administration
Drug Approval*/statistics & numerical data
Antineoplastic Agents/*therapeutic use
European Union/organization & administration ; Humans ; Uncertainty ; United Kingdom
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies